Experienced in Primitive Neuroectodermal Tumor (PNET)

Dr. Sami G. Diab

Hematology Oncology | Oncology | Hematology
Intermountain Medical Group Denver, LLC
340 Exempla Cir, 300 Lafayette Clinic Neuro, 
Lafayette, CO 
Accepting New Patients
Experienced in Primitive Neuroectodermal Tumor (PNET)
Intermountain Medical Group Denver, LLC
340 Exempla Cir, 300 Lafayette Clinic Neuro, 
Lafayette, CO 
OverviewInsuranceLocationsClinical ResearchSimilar Doctors

Overview

Sami Diab is a Hematologist Oncology specialist and an Oncologist in Lafayette, Colorado. Dr. Diab is rated as an Experienced provider by MediFind in the treatment of Primitive Neuroectodermal Tumor (PNET). His top areas of expertise are Breast Cancer, Paget Disease of the Breast, Angiosarcoma, and Inflammatory Breast Cancer. Dr. Diab is currently accepting new patients.

His clinical research consists of co-authoring 13 peer reviewed articles and participating in 9 clinical trials. MediFind looks at clinical research from the past 15 years.

Specialties
Hematology Oncology
Oncology
Hematology
Licenses
Internal Medicine in CO
Hospital Affiliations
Saint Joseph Hospital
University Of Colorado Hospital Authority
Good Samaritan Medical Center LLC
Languages Spoken
English
Gender
Male

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Accepted insurance plans:

Aetna
  • EPO
  • HMO
  • POS
  • PPO
Anthem
  • EPO
  • HMO
  • POS
  • PPO
Blue Cross Blue Shield
  • EPO
  • HMO
  • POS
  • PPO
Cambia Health Solutions
  • EPO
  • INSURANCE PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • OTHER COMMERCIAL
  • OTHER MEDICARE
  • PPO
Capital Blue Cross
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • OTHER MEDICARE PART D
  • PPO
Cigna
  • EPO
  • HMO
  • PPO
Denver Health Medical Plan
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
Health Care Services Corporation
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • OTHER COMMERCIAL
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
  • PPO
Humana
  • HMO
  • INDEMNITY
  • POS
  • PPO
Managed Medicaid
  • OTHER MANAGED MEDICAID
Medica
  • EPO
  • HMO
  • PPO
Medicaid
  • OTHER MEDICAID
  • STATE MEDICAID
SelectHealth
  • HMO
  • POS
UnitedHealthcare
  • EPO
  • HMO
  • POS
  • PPO
Wellcare
  • EPO
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
View 10 Less Insurance Carriers -

Locations

INTERMOUNTAIN MEDICAL GROUP DENVER, LLC
340 Exempla Cir, 300 Lafayette Clinic Neuro, Lafayette, CO 80026
Other Locations
INTERMOUNTAIN MEDICAL GROUP DENVER, LLC
8350 Colorado Blvd, Unit 160, Firestone, CO 80504
INTERMOUNTAIN MEDICAL GROUP DENVER, LLC
1825 N Marion St, Denver, CO 80218

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

9 Clinical Trials

A Phase 1 Open-Label, Safety, Pharmacokinetic and Preliminary Efficacy Study of STRO-002, an Anti-Folate Receptor Alpha (FolRα) Antibody-Drug Conjugate (ADC), in Patients With Advanced Epithelial Ovarian Cancer (Including Fallopian Tube or Primary Peritoneal Cancers) and Endometrial Cancers
A Phase 1 Open-Label, Safety, Pharmacokinetic and Preliminary Efficacy Study of STRO-002, an Anti-Folate Receptor Alpha (FolRα) Antibody-Drug Conjugate (ADC), in Patients With Advanced Epithelial Ovarian Cancer (Including Fallopian Tube or Primary Peritoneal Cancers) and Endometrial Cancers
Enrollment Status: Completed
Publish Date: August 20, 2025
Intervention Type: Drug
Study Drug: STRO-002
Study Phase: Phase 1
Randomized, Double-blind, Phase 3 Study of Tucatinib or Placebo in Combination With Ado-trastuzumab Emtansine (T-DM1) for Subjects With Unresectable Locally-advanced or Metastatic HER2+ Breast Cancer (HER2CLIMB-02)
Randomized, Double-blind, Phase 3 Study of Tucatinib or Placebo in Combination With Ado-trastuzumab Emtansine (T-DM1) for Subjects With Unresectable Locally-advanced or Metastatic HER2+ Breast Cancer (HER2CLIMB-02)
Enrollment Status: Active_not_recruiting
Publish Date: August 07, 2025
Intervention Type: Drug
Study Drugs: tucatinib, T-DM1
Study Phase: Phase 3
MONARCH 2: A Randomized, Double-Blind, Placebo-Controlled, Phase 3 Study of Fulvestrant With or Without Abemaciclib, a CDK4/6 Inhibitor, for Women With Hormone Receptor Positive, HER2 Negative Locally Advanced or Metastatic Breast Cancer
MONARCH 2: A Randomized, Double-Blind, Placebo-Controlled, Phase 3 Study of Fulvestrant With or Without Abemaciclib, a CDK4/6 Inhibitor, for Women With Hormone Receptor Positive, HER2 Negative Locally Advanced or Metastatic Breast Cancer
Enrollment Status: Active_not_recruiting
Publish Date: April 20, 2025
Intervention Type: Drug
Study Drugs: Abemaciclib, Fulvestrant
Study Phase: Phase 3
Single Arm, Open Label Phase 1b/2 Study of SGN-LIV1A in Combination With Pembrolizumab for First-Line Treatment of Patients With Unresectable Locally-Advanced or Metastatic Triple-Negative Breast Cancer
Single Arm, Open Label Phase 1b/2 Study of SGN-LIV1A in Combination With Pembrolizumab for First-Line Treatment of Patients With Unresectable Locally-Advanced or Metastatic Triple-Negative Breast Cancer
Enrollment Status: Completed
Publish Date: December 20, 2024
Intervention Type: Drug
Study Drugs: ladiratuzumab vedotin, Pembrolizumab
Study Phase: Phase 1/Phase 2
A Phase 1/1b Study to Evaluate the Safety and Tolerability of Immunotherapy Combinations in Participants With Breast or Gynecologic Malignancies
A Phase 1/1b Study to Evaluate the Safety and Tolerability of Immunotherapy Combinations in Participants With Breast or Gynecologic Malignancies
Enrollment Status: Completed
Publish Date: May 24, 2024
Intervention Type: Drug
Study Drugs: Etrumadenant, IPI-549, Pegylated liposomal doxorubicin, Nab-paclitaxel
Study Phase: Phase 1
ENGOT-ov50 / GOG-3029 / INNOVATE-3: Pivotal, Randomized, Open-label Study of Tumor Treating Fields (TTFields, 200kHz) Concomitant With Weekly Paclitaxel for the Treatment of Recurrent Ovarian Cancer
ENGOT-ov50 / GOG-3029 / INNOVATE-3: Pivotal, Randomized, Open-label Study of Tumor Treating Fields (TTFields, 200kHz) Concomitant With Weekly Paclitaxel for the Treatment of Recurrent Ovarian Cancer
Enrollment Status: Completed
Publish Date: March 29, 2024
Intervention Type: Device, Drug
Study Drug: Paclitaxel
Study Phase: Phase 3
A Phase 1, Open-Label, Dose-Escalation Study to Evaluate the Safety and Tolerability of SGN-LIV1A in Patients With Metastatic Breast Cancer
A Phase 1, Open-Label, Dose-Escalation Study to Evaluate the Safety and Tolerability of SGN-LIV1A in Patients With Metastatic Breast Cancer
Enrollment Status: Completed
Publish Date: March 07, 2023
Intervention Type: Drug
Study Drugs: Ladiratuzumab vedotin, Trastuzumab
Study Phase: Phase 1
An International, Multi-Center, Open-Label, Randomized, Phase III Trial of Sacituzumab Govitecan Versus Treatment of Physician Choice in Patients With Metastatic Triple-Negative Breast Cancer Who Received at Least Two Prior Treatments
An International, Multi-Center, Open-Label, Randomized, Phase III Trial of Sacituzumab Govitecan Versus Treatment of Physician Choice in Patients With Metastatic Triple-Negative Breast Cancer Who Received at Least Two Prior Treatments
Enrollment Status: Completed
Publish Date: June 15, 2022
Intervention Type: Drug
Study Phase: Phase 3
A Phase 1b Study of Aurora A Kinase Inhibitor LY3295668 Erbumine in Monotherapy and Combination Therapy in Patients With Metastatic Breast Cancer Post CDK4/6 Inhibitor and Endocrine Therapy
A Phase 1b Study of Aurora A Kinase Inhibitor LY3295668 Erbumine in Monotherapy and Combination Therapy in Patients With Metastatic Breast Cancer Post CDK4/6 Inhibitor and Endocrine Therapy
Enrollment Status: Completed
Publish Date: June 01, 2020
Intervention Type: Drug
Study Phase: Phase 1
View 8 Less Clinical Trials

13 Total Publications

Safety and activity of anti-mesothelin antibody-drug conjugate anetumab ravtansine in combination with pegylated-liposomal doxorubicin in platinum-resistant ovarian cancer: multicenter, phase Ib dose escalation and expansion study.
Safety and activity of anti-mesothelin antibody-drug conjugate anetumab ravtansine in combination with pegylated-liposomal doxorubicin in platinum-resistant ovarian cancer: multicenter, phase Ib dose escalation and expansion study.
Journal: International journal of gynecological cancer : official journal of the International Gynecological Cancer Society
Published: December 23, 2022
Similar Doctors
Advanced in Primitive Neuroectodermal Tumor (PNET)
Dr. Hossein Maymani
Hematology Oncology | Hematology | Oncology
Advanced in Primitive Neuroectodermal Tumor (PNET)
Dr. Hossein Maymani
Hematology Oncology | Hematology | Oncology

Rocky Mountain Cancer Centers Llp

2030 Mountain View Ave, Suite 210, 
Longmont, CO 
 (14.8 miles away)
303-684-1900
Languages Spoken:
English
See accepted insurances
Offers Telehealth

Hossein Maymani is a Hematologist Oncology specialist and a Hematologist in Longmont, Colorado. Dr. Maymani is rated as a Distinguished provider by MediFind in the treatment of Primitive Neuroectodermal Tumor (PNET). His top areas of expertise are Lung Cancer, Chronic Lymphocytic Leukemia (CLL), Chronic B-Cell Leukemia (CBCL), and Richter Syndrome.

Advanced in Primitive Neuroectodermal Tumor (PNET)
Dr. Laurie L. Carr
Oncology | Hematology Oncology | Hematology
Advanced in Primitive Neuroectodermal Tumor (PNET)
Dr. Laurie L. Carr
Oncology | Hematology Oncology | Hematology

National Jewish Health

1400 Jackson St, 
Denver, CO 
 (17.7 miles away)
Languages Spoken:
English
See accepted insurances
Accepting New Patients
Offers Telehealth

Laurie Carr is an Oncologist and a Hematologist Oncology provider in Denver, Colorado. Dr. Carr is rated as a Distinguished provider by MediFind in the treatment of Primitive Neuroectodermal Tumor (PNET). Her top areas of expertise are Lung Cancer, Non-Small Cell Lung Cancer (NSCLC), Pleuropulmonary Blastoma, and Small Cell Lung Cancer (SCLC). Dr. Carr is currently accepting new patients.

Advanced in Primitive Neuroectodermal Tumor (PNET)
Dr. Gerald S. Falchook
Oncology
Advanced in Primitive Neuroectodermal Tumor (PNET)
Dr. Gerald S. Falchook
Oncology

Healthone Clinic Services - Oncology Hematology LLC

1800 Williams St, 300 Sarah Cannon Research, 
Denver, CO 
 (16.8 miles away)
720-754-2610
Languages Spoken:
English
See accepted insurances
Offers Telehealth

Gerald Falchook is an Oncologist in Denver, Colorado. Dr. Falchook is rated as a Distinguished provider by MediFind in the treatment of Primitive Neuroectodermal Tumor (PNET). His top areas of expertise are Colorectal Cancer, Melanoma, Glioma, and Astrocytoma.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Diab's expertise for a condition
ConditionClose
View All 10 Advanced Conditions
View All 47 Experienced Conditions
Want to save this doctor for later?
Sign Up
Is this your doctor?
Find A Second Opinion
Not sure about your diagnosis?
Check Your Symptoms
 
 
 
 
Learn about our expert tiers
Learn More
Are you the provider on this profile?
Claim Profile